Image by wallyg via Flickr The Manhattan Institute policy think-tank posts some commentary (including one by yours truly) on their Medical Progress Today section pertaining to the recent regulatory steps (backward).
Posts Tagged ‘economics’
Manhattan Institute ponders personal genomics regulation (wonks on wonks)
Posted in Uncategorized, tagged economics on April 21, 2008| Leave a Comment »
Fed chief signals healthcare marketplace reforms (ie. regulation)
Posted in Uncategorized, tagged economics on April 7, 2008| Leave a Comment »
Image by talkradionews via Flickr Amidst his hectic schedule managing the ongoing credit crisis, the New York Times notes that Federal Reserve chairman Ben Bernanke opened a bipartisan symposium which will, “lay the groundwork for what leaders of both parties predict will be a major push for health care legislation next year.” From the article, it seems that since healthcare accounts for such a large (and growing) slice of the federal budget pie, fixing inefficiency and disparity in healthcare will assuredly involve more legislation and regulation on a growing scale. The article bummed me out since I suppose it portends new and shifting regulatory layers that will just make it harder for entrepreneurial consumer-driven and health2.0 innovations to establish themselves. Coincidental bummer that this symposium was taking place on the day NY and CA were stifling a new genetic testing industry.
Biomarker-friendly healthcare marketplace unveiled
Posted in Uncategorized, tagged economics on March 1, 2008| Leave a Comment »
Dr. Scott Shreeve has a great post on the launch of “Carol” a new, open & transparent healthcare marketplace. With DNA Direct offering services there, its easy to see how biomarkers and biomarker-driven care can work within a consumer-driven business model. Exciting to see the future today !!
Relief of big pharma’s antidepressant blues is as easy as ABC ?
Posted in ABCB1, tagged Antidepressant, economics, Major depressive disorder, Personalized medicine on February 14, 2008| Leave a Comment »
Image via Wikipedia Recent meta-analytical research, “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy” (N Engl J Med 2008;358:252-60) reveals that while 94% of published antidepressant drug trials show positive findings, only 51% of all such (published and unpublished) trials show positive effects (with a range of effect sizes from 11-69%). This is probably not surprising to patients and physicians (investors? … well, maybe) who often search in vain, using trail and error, for a medication that can provide relief from major depression, one the the top disease burdens world-wide. Many have suggested that pharmacogenetics may provide a key to understanding the tremendous variability in medication response. For example, variations in the ABCB1, ATP-binding cassette sub-family B member 1, gene seem to predict who may show a response to certain antidepressants (citalopram, paroxetine, amitriptyline, and venlafaxine) medications, that are shuttled across the blood-brain-barrier endothelial membrane by ABCB1. In a pharmacogenetic medication trial involving 443 inpatients with depression who were treated at the Max Planck Institute of Psychiatry, the SNPs 2032583, rs2235015, rs2032583 and rs2235015 predict significantly different time course of response to treatment over 6 weeks. The paper, “Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression” (doi: 10.1016/j.neuron.2007.11.017) is an example of pure and applied science at is best. The results pose a vexing dilemma for “really big” pharma however since the market size of genetic responders is obviously much smaller than market at large. Nevertheless, it seems inexorable change is underway.
Timothy Stoltzfus Jost nails consumer-driven healthcare in a pre-health2.0 kind of way
Posted in Uncategorized, tagged economics, Health insurance on September 23, 2007| Leave a Comment »
There is no doubt that -omics and digital-bio is improving healthcare, IF, you’re NOT one of the 50 million uninsured human beings in America who lack health insurance. As a fan of all things free-and-open, bioinformatic and health2.0, I was glad to read Timothy Stoltzfus Jost ‘s new book, Health Care at Risk: A Critique of the Consumer-Driven Movement. A review of the historical and economic foundations of the so-called ‘consumer-driven healthcare’ movement which is well underway (supported by leading candidates from both parties), Jost unpacks inefficiencies inherent to both private insurance systems (adverse selection – ‘sick people need NOT apply’) and to public systems (moral hazard and demand inducement – ‘hey dude, pass the twinkies and cigarettes, – no worries, I’ll just rely on my free healthcare’). The main arguments, from Jost, that stuck with me, are that the consumer-directed system, as it stands today, is one that is skewed to address the moral hazard conundrum, and this is not likely to resolve much of the current economic crisis since healthcare spending is distributed very asymmetrically (a tiny fraction of very sick people account for most of spending). Indeed, Jost suggests the current consumer-directed healthcare movement (pass off the first $5,000 spending to the consumer) is likely to make matters worse before they get better. While sobering, the book may prompt a redoubling of the focus of the many free-and-open bioinformatic and health2.0 efforts working to enhance care and access for all.
GINA and the death of health insurance ?
Posted in Uncategorized, tagged economics, Health insurance on July 7, 2007| Leave a Comment »

- Image by Steve Rhodes via Flickr
I much enjoyed the recent article, “Do Not Ask or Do Not Answer” in the August 25th Economist. As genetic data begins to trickle into the hands of consumers, the debate on genetic privacy grows more intense. On the one hand, the article notes that the SRY gene has long been used to price insurance (its the gene that determines the male vs. female pathway during embryonic development – sorry males) and that a look at one’s parents and siblings gives a fairly decent sense of one’s genetic liabilities. On the other hand, the article notes a study showing that folks who find they carry a potent Alzheimer’s risk gene are more likely to purchase extra health insurance – thus out-gaming the insurance industry to their discontent. Both hands having acknowledged the disconnect, the article turns to the search for new financial strategies for the future when consumers possess detailed knowledge of their own genomes (speaking of which, take a moment to browse Jim Watson’s genome). Some of the solutions noted were a form of compulsory universal coverage where neither side can outgame the other, HSA’s where out-of-pocket expenses are paid from individual tax free investment account and other new business models such as provided by RedBrick Health where benefits are maximized by optimizing participants behavior. The science is moving fast. Will the health insurance markets keep up?
Interview central for discussions on healthcare economics
Posted in Uncategorized, tagged economics, Health insurance on June 21, 2007| Leave a Comment »
If I may shill for the corporate medical industrial complex for a moment … I much enjoyed the video interviews found at the Corporate Research Group. Regina Herzlinger predicts universal coverage, but not a single-payer system – rather a system where consumers have choices. How to decide which plan to chose ???
Where’s the alpha in healthcare?
Posted in Uncategorized, tagged economics on June 14, 2007| Leave a Comment »
Its hard not to gawk at the sub-prime mortgage spectacle these days … seems like there are limits to borrowing – who’d a thunk? I was struck reading the news of one fund, Global Alpha, a quantitative strategy fund run by the elite Goldman Sachs firm. Wow, if the brightest of the bright can stumble, I suppose no one will escape unscathed. In any case, the name of the fund ‘alpha‘ – refers to an aspect of the capital asset pricing model (the y intercept) that accounts for endogenous, organic growth of an asset, instead of growth driven by an overall rising marketplace (this type of illusory growth is denoted by beta). I’m not a successful investor, but the ability to identify sources of alpha seems like an important skill.
Which eventually got me wondering … where is the alpha in healthcare? What drives organic growth of the for-profit sector of the healthcare industrial complex? Creativity? New technology? Efficient use of technology? Demographic shifts? Cost-cutting and adverse selection (think Sicko by Michael Moore)? I suppose all of the above.
But, in some ways, the concept of alpha as embodied in the CAPM doesn’t seem to apply quite right … I mean, if we’re doing a great job helping folks stay healthy, shouldn’t that reduce the demand for services? Where’s the growth (alpha) in that?
What business model generates a common benefit such as health and the type of financial alpha needed to attract investors?
Sobering article on economics of preventative care
Posted in Uncategorized, tagged Consumer, economics, New York Times on June 7, 2007| Leave a Comment »
David Leonhardt’s recent New York Times article “Free Lunch on Health? Think Again” on the economics of preventative medicine suggests the cost of preventative care for the vast majority of healthy individuals does not save money in the long run. The argument seems to go something like … most of the cost of healthcare goes toward a small percent of very sick people and that spending on preventative care does not do much to reduce the size of this already small group. It seems that spending a ‘little on a lot’ of healthy people is equivalent to spending a ‘lot on a little’ group of people.
This seems to me to be one of the big challenges for personalized medicine. How will bio-marker and IT-technologies be deployed to save money? Perhaps when it is cheap, reliable, trustworthy, consumer-friendly and useful enough to encourage individuals to get involved (ie. rewards consumers for paying out of their own pockets) ? Hmmm.
The new financial order – for healthcare?
Posted in Uncategorized, tagged Business, economics, Health, Health insurance on April 30, 2007| Leave a Comment »
In, The New Financial Order, professor Robert Shiller offers an in-depth analysis of how finance can and should be used to improve the human condition. By appropriately adapting financial instruments with risk, the consequences of many of life’s sudden shocks (natural disaster, loss of job, health crisis etc.) are readily ameliorated. Although he does not cover health insurance directly, his suggestions on how to better manage other types of risk point to an alternative viewpoint … away from the polarized “universal coverage” vs. “consumer-driven private coverage” debate. New bioinformatic strategies for managing health risk could readily be linked to financial instruments that more efficiently provide buffering to the economic consequences of illness.
James R. Knickman’s views on making an impact in healthcare
Posted in Uncategorized, tagged economics, Non-profit organization on April 14, 2007| Leave a Comment »
I much enjoyed listening to the remarks of James R. Knickman, President and Chief Executive Officer, New York State Health Foundation. He reviewed some highlights of his career and the inner thoughts processes of non-profit foundations taking on complex problems. One particular topic he emphasized is the interest that foundations have in better understanding how new technology will alter the healthcare landscape.
![Reblog this post [with Zemanta]](https://i0.wp.com/img.zemanta.com/reblog_e.png)
![Reblog this post [with Zemanta]](https://i0.wp.com/img.zemanta.com/reblog_c.png)